3. Development of Pharmacological Chaperone Therapy for Neuronopathic Gaucher Disease

Japanese Journal of Clinical Pharmacology and Therapeutics - Japan
doi 10.3999/jscpt.48.114
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Related search

Arimoclomol as a Potential Therapy for Neuronopathic Gaucher Disease

2018English

Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria

Scientific Reports
Multidisciplinary
2016English

AB120. Cholelithiasis in a Filipino Child With Chronic Neuronopathic Gaucher Disease: Report of a Case

Annals of Translational Medicine
Medicine
2017English

Cost-Effectiveness of Enzyme Replacement Therapy for Type 1 Gaucher Disease

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

PP044 Adherence to Enzyme Replacement Therapy in Gaucher Disease

International Journal of Technology Assessment in Health Care
Health Policy
2017English

Three Classes of Glucocerebrosidase Inhibitors Identified by Quantitative High-Throughput Screening Are Chaperone Leads for Gaucher Disease

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2007English

Psy97 - Cost-Effectiveness Analysis of Enzyme Replacement Therapy for Type 1 Gaucher Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Chitinase in Humans Is a Marker for Gaucher Disease. Potential for Monitoring Therapy. 850

Pediatric Research
Child HealthPediatricsPerinatology
1996English

Structural Development Study of a Novel Pharmacological Chaperone for Folding-Defective Rhodopsin Mutants Responsible for Retinitis Pigmentosa

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy